PENSACOLA, Fla. (WEAR) — Half a million people this year will get an infection called C. diff. It ranges from uncomfortable to life-threatening. And in more and more cases, doctors are turning to an ...

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and ...

According to the Centers for Disease Control and Prevention, 47 million courses (PDF) of antibiotics were prescribed for infections that didn’t need them in 2018. And taking antibiotics is “like ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Please provide your email address to receive an email when new articles are posted on . Results from a real-word study showed fecal microbiota transplantation for Clostridioides difficile infection ...

Paul Feuerstadt, MD, and Louis Korman, MD, spoke with Becker’s about how a study published in The New England Journal of Medicine could change how the gastroenterology industry treats Clostridioides ...

A new microbiome-based treatment for Clostridioides difficile infection showed success in reducing recurrence of the infection at 8 weeks, according to preliminary results released by the manufacturer ...

LONDON--(BUSINESS WIRE)--The global clostridium difficile treatment market size is expected to grow by USD 159.87 million as per Technavio. This marks a significant market growth compared to the 2019 ...